GB2402335A - Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form - Google Patents

Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form Download PDF

Info

Publication number
GB2402335A
GB2402335A GB0419971A GB0419971A GB2402335A GB 2402335 A GB2402335 A GB 2402335A GB 0419971 A GB0419971 A GB 0419971A GB 0419971 A GB0419971 A GB 0419971A GB 2402335 A GB2402335 A GB 2402335A
Authority
GB
United Kingdom
Prior art keywords
phenyl
bipyridazine
pyrazolo
methanesulfonyl
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0419971A
Other versions
GB0419971D0 (en
GB2402335B (en
Inventor
Jonathan Appleby
Martin Rolfe Hill
Simon Joseph Holland
Stephanie Lynn Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of GB0419971D0 publication Critical patent/GB0419971D0/en
Publication of GB2402335A publication Critical patent/GB2402335A/en
Application granted granted Critical
Publication of GB2402335B publication Critical patent/GB2402335B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides a pharmaceutical composition comprising a compound of formula (I) and pharmaceutically acceptable salts thereof, in which the compound is present in solid particles in nanoparticulate form, in admixture with one or more pharmaceutically acceptable carriers or excipients.

Description

GB 2402335 A continuation (72) Inventor(s): Jonathan Appleby Martin Rolfe
Hill Simon Joseph Holland Stephanie Lynn Pearson (74) Agent and/or Address for Service: GlaxoSmithKline Corporate Intellectual Property, CN9.25.1, 980 Great West Road, BRENTFORD, Middlesex, TWO 9GS, United Kingdom
GB0419971A 2002-03-15 2003-03-13 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form Expired - Fee Related GB2402335B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0206200.8A GB0206200D0 (en) 2002-03-15 2002-03-15 Pharmaceutical compositions
PCT/EP2003/002698 WO2003077920A1 (en) 2002-03-15 2003-03-13 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo’1,5-bipyridazine in nanoparticulate form

Publications (3)

Publication Number Publication Date
GB0419971D0 GB0419971D0 (en) 2004-10-13
GB2402335A true GB2402335A (en) 2004-12-08
GB2402335B GB2402335B (en) 2005-10-12

Family

ID=9933079

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0206200.8A Ceased GB0206200D0 (en) 2002-03-15 2002-03-15 Pharmaceutical compositions
GB0419971A Expired - Fee Related GB2402335B (en) 2002-03-15 2003-03-13 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB0206200.8A Ceased GB0206200D0 (en) 2002-03-15 2002-03-15 Pharmaceutical compositions

Country Status (21)

Country Link
US (1) US20050153967A1 (en)
EP (1) EP1485098B1 (en)
JP (1) JP2005520824A (en)
KR (1) KR20040091133A (en)
CN (1) CN1642549A (en)
AT (1) ATE350038T1 (en)
AU (1) AU2003208709A1 (en)
BR (1) BR0307427A (en)
CA (1) CA2478758A1 (en)
DE (1) DE60310896T2 (en)
EA (1) EA007201B1 (en)
EC (1) ECSP045295A (en)
ES (1) ES2277634T3 (en)
GB (2) GB0206200D0 (en)
IS (1) IS7378A (en)
MX (1) MXPA04009008A (en)
NO (1) NO20043889L (en)
NZ (1) NZ534179A (en)
PL (1) PL372932A1 (en)
WO (1) WO2003077920A1 (en)
ZA (1) ZA200406553B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60305053T2 (en) 2002-08-19 2006-08-31 Glaxo Group Ltd., Greenford Pyrimidine derivatives as selective COX-2 inhibitors
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041760A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
WO2002000196A2 (en) * 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6451794B1 (en) * 1997-09-05 2002-09-17 Smithkline Beecham Corporation 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041760A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
WO2002000196A2 (en) * 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process

Also Published As

Publication number Publication date
NO20043889L (en) 2004-09-16
GB0419971D0 (en) 2004-10-13
ES2277634T3 (en) 2007-07-16
JP2005520824A (en) 2005-07-14
BR0307427A (en) 2004-12-28
ECSP045295A (en) 2004-10-26
EA007201B1 (en) 2006-08-25
NZ534179A (en) 2006-07-28
CA2478758A1 (en) 2003-09-25
GB2402335B (en) 2005-10-12
EA200400864A1 (en) 2005-02-24
EP1485098B1 (en) 2007-01-03
DE60310896D1 (en) 2007-02-15
ATE350038T1 (en) 2007-01-15
KR20040091133A (en) 2004-10-27
AU2003208709A1 (en) 2003-09-29
ZA200406553B (en) 2005-09-22
MXPA04009008A (en) 2004-12-07
PL372932A1 (en) 2005-08-08
US20050153967A1 (en) 2005-07-14
GB0206200D0 (en) 2002-05-01
EP1485098A1 (en) 2004-12-15
CN1642549A (en) 2005-07-20
DE60310896T2 (en) 2007-05-10
WO2003077920A1 (en) 2003-09-25
IS7378A (en) 2004-07-29

Similar Documents

Publication Publication Date Title
LUC00155I1 (en)
WO2004066910A3 (en) Controlled release modifying complex and pharmaceutical compositions thereof
CA2313783A1 (en) Pharmaceutical compositions of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a salt thereof
HUP0303886A3 (en) New film coating composition for coating of pharmaceutical compositions
WO2003002136A3 (en) Stable formulation of modified glp-1
IL158200A0 (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant
CA2414018A1 (en) 2-aminocarbonyl-9h-purine derivatives
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
WO2005002542A3 (en) Nanoparticulate meloxican formulations
WO2006033700A3 (en) Her2 antibody composition
AU2003245313A1 (en) Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
CA2448035A1 (en) New pharmaceutical composition
AU2001284985A1 (en) Compounds and compositions for delivering active agents
IL174665A0 (en) Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
JP2002510633A5 (en)
WO2007022023A3 (en) Film forming spreading agents
NO20041059L (en) Combination of selected opioids with muscarinic antagonists for the treatment of urinary incontinence
CA2083639A1 (en) Substituted phenyl phenol leukotriene antagonists
AU2003217712A1 (en) Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
GB2402335A (en) Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form
AU2002364953A1 (en) Topoisomerase poison agents
WO2006005611A3 (en) Glucocorticoid 16alpha,17.alpha.-isoxazolidines as anti-inflammatory agents
AU5705099A (en) Compounds useful as aicarft inhibitors
EP1378246A4 (en) Remedies for arteriosclerosis
WO2002100338A3 (en) Compound and composition for delivering active agents

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20090313

S73 Revocation on comptroller's initiative (section 73/patents act 1977)

Free format text: PATENT REVOKED; PATENTS REVOKED UNDER SECTION 73(2)